Research outlook

Where epilepsy treatment is heading

Epilepsy · Updated Nov 15, 2026

About 3.4 million Americans have epilepsy. Most become seizure-free with one or two medicines, but about 1 in 3 keep having seizures despite trying several (drug-resistant epilepsy). For them, options include newer medicines such as cenobamate, surgery or laser ablation, nerve stimulation devices and the ketogenic diet. Research is bringing the first new drug classes in years, gene-targeted treatments for rare genetic epilepsies, and cell and gene therapies that could repair the seizure focus itself.

  1. Now

    Nov 2026

    A new class for focal seizuresHappened 53.2% median seizure drop

    Azetukalner, a potassium-channel opener, cut monthly focal seizures by a median 53.2% vs 10.4% with placebo in phase 3.

    53.2%: median drop in monthly seizures with 25 mg, vs 10.4% with placebo.

    Cenobamate makes many seizure-freeHappened 52.4% seizure-free

    In a large Asian trial, 52.4% on the highest dose were seizure-free during maintenance vs 2.6% on placebo.

    52.4%: seizure-free during maintenance with 400 mg, vs 2.6% with placebo.

    Precision drugs for severe childhood epilepsiesHappened 59.8% drop in motor seizures (bexicaserin)

    Bexicaserin cut motor seizures 59.8% vs 17.4% in DEEs; zorevunersen, which restores a missing sodium channel in Dravet syndrome, was followed by large seizure drops in open-label studies.

    59.8%: median drop in motor seizures with bexicaserin, vs 17.4% with placebo.

  2. 6 months

    by May 2027

    BHV-7000 phase 3 resultsLikely

    Biohaven's RISE 2 and RISE 3 (390 people each) test another potassium-channel opener in drug-resistant focal epilepsy; due October and December 2026.

    Bexicaserin for severe childhood epilepsiesLikely 59.8% drop in motor seizures

    DEEp SEA (367 people) tests bexicaserin in Dravet, Lennox-Gastaut and other DEEs; due October 2026.

    59.8%: median drop in motor seizures, vs 17.4% with placebo.

    Azetukalner approval applicationPossible 53.2% median seizure drop

    After positive phase 3 results, Xenon could submit azetukalner to regulators.

    53.2%: median drop in monthly seizures with 25 mg, vs 10.4% with placebo.

  3. 12 months

    by Nov 2027

    Zorevunersen phase 3Possible 58.82% or greater seizure drop (open-label)

    Stoke's EMPEROR (170 children) is the first placebo-controlled test of a disease-targeting drug for Dravet syndrome; due March 2027.

    58.82%: or greater median drop in convulsive seizures at the highest dose, without a comparison group.

    Azetukalner for generalized seizuresPossible

    X-ACKT (160 people) tests azetukalner for primary generalized tonic-clonic seizures; due April 2027.

    Vormatrigine, a sodium-channel drugPossible

    Praxis's POWER2 (300 people) is due January 2027.

  4. 3 years

    by late 2029

    Cell therapy for temporal lobe epilepsyPossible

    Neurona's EPIC (88 people, due February 2029) implants lab-grown calming nerve cells into the seizure focus, instead of removing brain tissue.

    A drug for juvenile myoclonic epilepsyPossible

    Jazz's JZP926 trial (260 people) is due August 2028.

  5. 5 years

    by late 2031

    More targeted focal-epilepsy pillsPossible

    Rapport's RAP-219 trials (645 people, due July 2029) target a protein found mainly in the brain areas where focal seizures start.

    Gene therapy and preventionLong shot

    Gene therapy for temporal lobe epilepsy (AMT-260) and trials to prevent epilepsy after brain injury could change care for some groups.

Happened Likely Possible Long shot

The research paths

Heating up

Potassium-channel openers

53.2% median seizure drop
Details and 4 trialsHide
Heating up

Precision drugs for genetic epilepsies

59.8% drop in motor seizures
Details and 3 trialsHide
Active

New pills for focal seizures

52.4% seizure-free
Details and 5 trialsHide
Early

Cell and gene therapy

Details and 3 trialsHide

Borrowed from other conditions

From Depression research

Azetukalner

Phase 3

Also in phase 3 trials for major depression and bipolar depression.

From Serotonin drugs like fenfluramine

Bexicaserin

Phase 3

Targets the same 5-HT2C receptor thought to explain fenfluramine benefit in Dravet syndrome, without its other effects.

Open to join now

See every recruiting Epilepsy trial →

When the trials finish

Completion dates the trials registered. Results usually follow 3 to 12 months later.

2026202720282029203020312032Today
BHV-7000 for focal seizures (RISE 3)Potassium-channel openers
Oct 2026
Bexicaserin for DEEs (DEEp SEA)Precision drugs for genetic epilepsies
Oct 2026
Nov 2026
BHV-7000 for focal seizures (RISE 2)Potassium-channel openers
Dec 2026
Relutrigine for DEEs (EMERALD)Precision drugs for genetic epilepsies
Dec 2026
Dec 2026
Vormatrigine for focal seizures (POWER2)New pills for focal seizures
Jan 2027
Zorevunersen for Dravet syndrome (EMPEROR)Precision drugs for genetic epilepsies
Mar 2027
Jan 2028
Vormatrigine for focal seizuresNew pills for focal seizures
May 2028
JZP926 for juvenile myoclonic epilepsyNew pills for focal seizures
Aug 2028
Feb 2029
RAP-219 for focal seizures (FOCUS 1)New pills for focal seizures
Jul 2029
RAP-219 for focal seizures (FOCUS 2)New pills for focal seizures
Jul 2029

What just happened

Azetukalner cuts focal seizures in phase 3

X-TOLE2, JAMA Neurology.

Zorevunersen early results in Dravet syndrome
Bexicaserin reduces seizures in DEEs

PACIFIC, Epilepsia.

Standard treatment today

How to read this page, and sourcesHow to read this page, and sources

See Epilepsy trials recruiting now →

Last reviewed 2026-11-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.